Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) closed at $10.45 on October 26, 2026, down 0.76% on the day. The stock trades 61.2% below its 52-week high of $26.95 and 63.5% above its 52-week low of $6.39. Over the past year, it gained 43.3%. Corvus Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 24, 2025, CRVS closed higher on 119 days (47%). Its best day was January 20, 2026 (+165.96%) and its worst was May 14, 2026 (-13.79%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Find more stocks like CRVS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.